Asia-Pacifics Glioblastoma Multiforme Treatment Market Value to More than Double by 2020
The Glioblastoma Multiforme (GBM) therapeutics market in Asia-Pacific (APAC) will more than double in value, from $49.4 million in 2013 to $105.8 million by 2020, at a Compound Annual Growth Rate (CAGR) of 11.5%, says a new report from business intelligence provider GBI Research.
The company’s latest report* states that this impressive growth will result from the anticipated approval and market entries of Rindopepimut, Cotara and Avastin in some APAC countries during the forecast period.
Vijaya Vulapalli, Senior Analyst for GBI Research, says: “The APAC region boasts a strong GBM pipeline, which also includes carmustine implants, currently being developed in China. Novel therapies Rindopepimut and Cotara in particular could have a significant bearing on APAC’s GBM treatment landscape.
“Phase II clinical studies of Rindopepimut demonstrated a relatively high median overall survival (OS) rate among patients. Meanwhile, Cotara’s Phase II studies showed similar OS to Avastin, with slightly more progression-free survival improvement in recurrent GBM. As a single-infusion therapy, Cotara is likely to become an effective second-line treatment option for patients.”
However, GBI Research states that even if these therapies prove successful in late-stage clinical trials, they will experience low uptake in their respective markets due to their high prices and lack of patient access to medicines, mainly in China and India.
Furthermore, APAC’s GBM treatment space is still expected to require new drugs with better efficacy and improved prognosis.
Vulapalli continues: “One of the key reasons for the lack of efficacy exhibited by most therapies is their inability to penetrate the blood–brain barrier, and an urgent unmet need will remain over the forecast period for drugs that can achieve this.
“Efficacy also remains low because therapeutic resistance develops due to the disease heterogeneity, which is believed to be increased by genetic variations arising from mutations. A combined therapy that acts on multiple tumour signaling pathways, rather than a single molecular target, may therefore be more effective and result in a better prognosis,” the analyst concludes.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance